Pfizer CEO Pens Open Letter on COVID-19 Vaccine IP Waiver

Published date11 May 2021
Subject MatterPatents,Life Sciences,Waivers,Vaccinations,Pfizer,Pharmaceutical Patents,Intellectual Property Protection,Pharmaceutical Industry,Coronavirus/COVID-19
AuthorDonald Zuhn
Law FirmMcDonnell Boehnen Hulbert & Berghoff LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT